Poly Medicure (POLYMED) Earnings Call Presentation

Polymed Overview - Polymed is a leading MedTech company in India with a global presence, serving over 125 countries[9] - The company has a significant manufacturing capacity of over 1.8 billion devices per year[14] - Polymed has a diverse product portfolio across 12 specialities[7] and holds over 334 patents[10] - Polymed's total income has grown at a CAGR of 22% from FY2022 to FY2025, reaching INR 1,670 Cr in FY2025[40] Acquisition of Pendracare Group - Polymed is acquiring 90% of Pendracare Group for an upfront equity consideration of approximately EUR 11 million, with a total upfront payout of around EUR 14.2 million including inter-group loan liabilities[44] - The acquisition includes taking over net external debt of EUR 2.9 million[44] - Pendracare's CY24 revenue was EUR 9.9 million, with a gross profit of EUR 7.3 million and EBITDA of EUR 1.4 million[44] - The EV/Revenue and EV/EBITDA multiples for the transaction are 1.83x and 13x respectively, based on CY24 financials[44] Strategic Rationale - The acquisition provides Polymed with a unique interventional cardiology consumable asset in Europe[1,48] - Polymed expects to generate annual EBITDA synergy of EUR 3-4 million in the next 3-4 years[68] - Pendracare has product registration in more than 60 countries[44,48]